Key Takeaways
- Mileutis has appointed Dr. Joachim Hasenmaier and Mr. Aaron Schacht to its Board of Directors.
- Both executives bring extensive experience in animal health and biotechnology.
- Dr. Hasenmaier previously led Boehringer Ingelheim’s Animal Health division and currently chairs other industry boards.
- Mr. Schacht is CEO of BiomEdit and a former executive at Elanco Animal Health.
- Mileutis is advancing antibiotic and hormone-free peptide-based therapies for the dairy industry.
Mileutis strengthens leadership with key board appointments
Mileutis, a biopharmaceutical company focused on antibiotic and hormone-free solutions for the dairy industry, announced the appointment of two seasoned executives to its Board of Directors. Dr. Joachim Hasenmaier and Mr. Aaron Schacht join the company as it prepares to advance its peptide-based therapies and expand its market presence.
David Javier Iscovich, CEO and Chairman of Mileutis, said, “The addition of Dr. Hasenmaier and Mr. Schacht to our Board marks a significant milestone. Their deep understanding of the animal health ecosystem, coupled with decades of experience leading innovation, acquisitions and growth, will further advance Mileutis’ role in the dairy industry.”
Dr. Joachim Hasenmaier brings global animal health leadership
With over 30 years in animal and human health, Dr. Hasenmaier joins Mileutis following senior leadership roles at Boehringer Ingelheim, where he served as Head of Animal Health and helped the division become a global leader. He is currently Chairman of IMV Technologies and ECO Animal Health.
“I’ve seen firsthand the urgent need for sustainable, science-backed alternatives to antibiotics in animal health,” said Dr. Hasenmaier. “Mileutis is on a clear path to delivering that, and I look forward to supporting their next stage of growth in the dairy industry.”
Aaron Schacht adds expertise in biotech and microbiome solutions
Mr. Schacht, CEO of BiomEdit, brings substantial experience in microbiome and synthetic biology. Prior to his current role, he held senior positions at Elanco Animal Health and Eli Lilly, overseeing acquisitions, R&D, and product launches.
“Mileutis is tackling one of the most pressing challenges in the dairy industry,” Schacht stated. “As the company enters this critical stage of bringing their antibiotic and hormone-free solutions to market, I’m honored to join the team and help the company succeed in addressing antimicrobial resistance.”
Mileutis focuses on sustainable dairy solutions
Mileutis is developing IMILAC™ and MILAC™, peptide-based therapies aimed at providing residue-free, sustainable alternatives to conventional antibiotics and hormones in dairy farming. The company’s solutions target the global demand for responsible animal health products, with potential benefits across the supply chain.
By appointing Dr. Hasenmaier and Mr. Schacht, Mileutis signals its intent to leverage industry expertise and scale its operations to meet rising market expectations.
